The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement
BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX) today announced an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.
The agreement between Crown Bioscience, a global technology platform for Oncology, and Cardiovascular and Metabolic Disease, and JAX, a non-profit biomedical research institution and worldwide provider of high-quality research models and services, facilitates the shared objective of both organizations; to accelerate and advance the rate of pre-clinical research and discovery.
As part of the agreement: CrownBio will advance the use of JAX® Mice in client research studies. CrownBio will increase the utilization and improve access of JAX research models, including humanized NSG(TM) and NSG(TM)-SGM3, thus advancing the research and translational efforts of organizations globally.
JAX research scientists will have select access to CrownBio's pre-clinical contract laboratory services, providing JAX scientists with additional resources and facilities in which to continue the search for cures for cancer and other diseases.
"The agreement with JAX heralds a significant step forward for Oncology and Immuno-Oncology pre-clinical research," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. "The utilization of JAX's scientific-leading humanized and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development."
Research teams at JAX, focused on understanding the genetic and biochemical signatures that can be targeted by next-generation precision medicines, will immediately begin leveraging CrownBio's vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
"The Jackson Laboratory's mission is to empower the global biomedical community in our shared quest to improve human health. By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services," stated Auro Nair, Ph.D., President of JAX® Mice, Clinical & Research Services. "Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilizing the world's largest collection of PDX and cell-line models and services from CrownBio."
About Crown Bioscience
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology and cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,900 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.
JAX Contact: Dr. Charles Miller Director of Marketing & Customer Support 207-288-6895 email@example.com Crown Bioscience Media Contact: Gavin Cooper Executive Director Marketing firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
OpenAire brings in the sun with retractable structures across Europe22.9.2017 08:00 | Pressemelding
OAKVILLE, Ontario, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Venues around the world have been thrilled by OpenAire's retractable roof and enclosure designs since 1989. In 28 years, OpenAire's team of experts has completed nearly 1,000 unique retractable roof enclosures and operable skylights for venues of every size and kind internationally, including many groundbreaking designs across Europe. From Russia to warm and sunny Gibraltar, OpenAire has provided many commercial enterprises, resorts and even some private residences with beautiful retractable enclosures that suit their location and climate perfectly. OpenAire works closely with every client from the start, providing them with the flexibility to make their visions a reality. Many clients across Europe have seen increased business and excellent reviews after building an OpenAire solution. Some notable OpenAire designs include: Aqua Sferra's record-breaking 5,667 m2 (60,999 sq. ft.) free-standing aluminum dome housing its indoor
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressemelding
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressemelding
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressemelding
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressemelding
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
Senegal and France to host Global Partnership for Education Financing Conference20.9.2017 23:00 | Pressemelding
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- The Global Partnership for Education (GPE) is delighted that the governments of Senegal and France will co-host its financing conference, which will take place on February 8, 2018 in Dakar, Senegal. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d3003cff-ee20-409f-9729-9a9cef1d4d3e A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0a7eebb6-66b3-438b-904e-efeff83d94cf The announcement of the co-hosting was made by Presidents Macky Sall of Senegal and Emmanuel Macron of France at a high-level event on education financing held at the United Nations, which was attended by Secretary General António Guterres, several heads of state and leaders on global education. " The Global Partnership for Education has made substantial investments in education helpin
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom